Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Regeneron acquires antibody rights from Sanofi
June 2013
SHARING OPTIONS:

TARRYTOWN, N.Y.Regeneron Pharmaceuticals Inc. has acquired full exclusive rights to two preclinical programs of novel antibodies that were previously included in the company's antibody collaboration with Sanofi. Regeneron now holds full rights to antibodies that target the PDGF family of receptors and ligands in ophthalmology and all other indications, and antibodies targeting the ANG2 receptor and ligand in ophthalmology. The company will pay Sanofi $10 million up front and up to $40 million in development milestone payments for the PDGF antibodies, and $10 million up front and up to $5 million in a development milestone for the ANG2 antibodies. Sanofi is also entitled to sales royalties on both programs. Sanofi retains the rights to ANG2 antibodies beyond the indication of ophthalmology, which will continue to be developed by both companies under their collaboration agreement.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.